Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Extrawell Pharmaceutical Holdings Limited ( (HK:0858) ) has shared an update.
Extrawell Pharmaceutical Holdings Limited, a Hong Kong-listed pharmaceutical company focused on the development, manufacture and sale of healthcare and drug products in Greater China, has announced the composition of its board and key governance committees effective 1 January 2026. The company confirmed a board led by Chairman Dr. Xie Yi and CEO Dr. Guo Yi, supported by executive and independent non-executive directors, and detailed the structure of its Audit, Remuneration and Nomination Committees, with independent non-executive director Mr. Fang Lin Hu chairing both the Audit and Remuneration Committees and Dr. Xie Yi chairing the Nomination Committee, underscoring the firm’s emphasis on corporate governance and oversight as it heads into the new year.
The most recent analyst rating on (HK:0858) stock is a Hold with a HK$0.09 price target. To see the full list of analyst forecasts on Extrawell Pharmaceutical Holdings Limited stock, see the HK:0858 Stock Forecast page.
More about Extrawell Pharmaceutical Holdings Limited
Extrawell Pharmaceutical Holdings Limited is a Hong Kong-listed pharmaceutical company engaged in the development, manufacture and sale of pharmaceutical products, with a focus on the healthcare and drug markets in Greater China.
Average Trading Volume: 2,443,050
Technical Sentiment Signal: Hold
Current Market Cap: HK$234.6M
See more data about 0858 stock on TipRanks’ Stock Analysis page.